Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gerald Heulitt

Urology North Little Rock, AR Medical Doctor

NPI 1366739971 CMS profile 943180

4200 Stockton Dr, North Little Rock, AR 72117

Open in the dashboard

General payments

$9,336

209 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$500 paid to institutions, not to them · program year 2024

Through program year 2025, Gerald Heulitt of North Little Rock, AR is reported in the CMS Open Payments database as having received $9,336 across 209 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $500 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 79th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,076 37
2024 General $1,364 39
2023 General $4,596 48
2022 General $1,245 30
2021 General $276 15
2020 General $313 18
2019 General $467 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gerald Heulitt
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Gerald Heulitt were reported at $1,076. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Gerald Heulitt Urology median Middle half National median
2019 $467 $480 $147–$1,201 $163
2020 $313 $246 $87–$645 $114
2021 $276 $358 $111–$1,000 $132
2022 $1,245 $476 $143–$1,263 $149
2023 $4,596 $560 $168–$1,461 $160
2024 $1,364 $563 $170–$1,464 $164
2025 $1,076 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,395 1 payment
  2. Palette Life Sciences, Inc. $1,352 5 payments
  3. Myriad Genetic Laboratories, Inc. $967 12 payments
  4. Janssen Biotech, Inc. $828 25 payments
  5. Dendreon Pharmaceuticals LLC $757 16 payments
  6. Astellas Pharma US Inc $549 23 payments
  7. Novartis Pharmaceuticals Corporation $399 21 payments
  8. Myovant Sciences Inc. $362 10 payments
  9. Sumitomo Pharma America, Inc. $360 14 payments
  10. Pfizer Inc. $339 15 payments
  11. Other $2,029 67 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,713 202 payments
  2. Consulting Fee $1,395 1 payment
  3. Travel and Lodging $988 2 payments
  4. Education $240 4 payments
Products named General payments · program years 2019–2025
  1. ERLEADA $810 24 payments
  2. PROVENGE $757 16 payments
  3. myRisk $735 8 payments
  4. ORGOVYX $668 21 payments
  5. XTANDI $533 27 payments
  6. PLUVICTO $399 21 payments
  7. MYRBETRIQ $180 12 payments
  8. AQUABEAM ROBOTIC SYSTEM $178 4 payments
  9. BARRIGEL $163 4 payments
  10. UROLIFT $161 2 payments
  11. Other $2,459 95 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

1,266

Median for Urology: 1,053

Drug cost

$1,495,010

Median for Urology: $101,464

Branded share of claims

26.5%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Erleada Apalutamide Brand 65 $938,256
Xtandi Enzalutamide Brand 32 $451,990
Orgovyx Relugolix Brand 22 $54,464
Myrbetriq Mirabegron Brand 31 $32,986
Eliquis Apixaban Brand 11 $6,474
Tamsulosin Hcl Generic 443 $5,293
Oxybutynin Chloride Er Oxybutynin Chloride Brand 138 $1,970
Finasteride Generic 177 $1,667
Megestrol Acetate Generic 49 $901
Solifenacin Succinate Generic 21 $340

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 157 billing codes

Paid by Medicare

$651,998

Of which drugs: $144,555

Medicare patients

776

Average age 75

Services billed

11,034

175 women, 601 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 47%
Arthritis 45%
Ischemic heart disease 42%
Diabetes 38%
Chronic kidney disease 33%
Depression 23%
Heart failure 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 30 3,780 $77,568
Leuprolide injectable, camcevi, 1 mg J1952 Office 21 882 $39,873

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PROVENGE
  • Dendreon Pharmaceuticals LLC $255
$255 — —
ORGOVYX
  • Sumitomo Pharma America, Inc. $86
  • PFIZER INC. $23
$109 22 —
PLUVICTO
  • Novartis Pharmaceuticals Corporation $89
$89 — —
XTANDI
  • Astellas Pharma US Inc $63
  • PFIZER INC. $23
$85 32 —
ERLEADA
  • Janssen Biotech, Inc. $60
$60 65 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

209 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record